Subscribe To
AGNPF / Algernon Pharmaceuticals begins manufacturing Repirinast and launches new chronic kidney disease research program
AGNPF News
By Proactive Investors
June 27, 2023
Algernon Pharma considers potential spin-off of its chronic cough research program
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has said it is considering the potential spin-off of its NP-120 (Ifenprodil) chronic cough resea more_horizontal
By Proactive Investors
June 5, 2023
Algernon Pharmaceuticals subsidiary completes DMT escalating dose study
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has successfully completed dosing of the th more_horizontal
By Proactive Investors
May 31, 2023
Algernon Pharmaceuticals receives Notice of Allowance from Japanese Patent Office for Repirinast
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the Japanese Patent Office (JPO) for a patent ap more_horizontal
By Proactive Investors
April 17, 2023
Algernon Pharma receives Notice of Allowance from US Patent and Trademark Office for Repirinast
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said it has received a Notice of Allowance from the United States Patent and Trademark Office (US more_horizontal
By Proactive Investors
April 4, 2023
Algernon Pharmaceuticals announces successful dosing of second cohort in Phase 1 DMT clinical study
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its subsidiary Algernon NeuroScience (AGN Neuro) has completed dosing of the second cohort more_horizontal
By Proactive Investors
April 3, 2023
Algernon Pharma says wholly-owned subsidiary's Reg A+ offering gets US SEC qualification
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) said its wholly-owned subsidiary, Algernon NeuroScience (AGN Neuro), has qualified its Form 1-A o more_horizontal
By Proactive Investors
March 21, 2023
Algernon Pharmaceuticals to raise $2.4M by way of rights offering
Algernon Pharmaceuticals Inc announced that it is undertaking a rights offering to raise gross proceeds of approximately $2,416,747. The Canadian clin more_horizontal
By Proactive Investors
March 2, 2023
Former NFL neurologist joins Algernon's program using DMT to treat traumatic brain injury
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has engaged Dr David Brody, an expert neurologist, as a consultant to support the company's clini more_horizontal